SLC35E4: A Protein Targeted for Drug Development and Diagnosis

Target Name: SLC35E4

NCBI ID: G339665

SLC35E4

SLC35E4: A Protein Targeted for Drug Development and Diagnosis

SLC35E4, also known as SLC35E4 variant 1, is a protein that is expressed in various tissues throughout the body. It is a member of the SLC family, which is known for its involvement in the transport of various molecules across cell membranes. One of the unique aspects of SLC35E4 is its expression pattern, which is different from that of other SLC proteins. While most SLC proteins are predominantly expressed in the brain, SLC35E4 is expressed in the heart, liver, and pancreas, among other tissues.

The SLC35E4 protein is involved in the transport of a variety of different molecules, including ions, proteins, and nucleic acids. It is also involved in the regulation of various cellular processes, including cell signaling, DNA replication, and metabolism. SLC35E4 has been shown to play a role in a number of diseases, including heart failure, obesity, and diabetes.

One of the reasons why SLC35E4 is such an interesting drug target is its unique expression pattern. Unlike most SLC proteins, which are predominantly expressed in the brain, SLC35E4 is expressed in multiple tissues throughout the body. This makes it more difficult to target the protein specifically and may limit its effectiveness as a drug. However, there are efforts being made to develop compounds that can specifically target SLC35E4, potentially allowing for more effective treatment of diseases associated with this protein.

Another reason why SLC35E4 is a promising drug target is its involvement in various diseases. SLC35E4 has been shown to be involved in the regulation of cellular processes that are important in the development and progression of a number of diseases, including heart failure, obesity, and diabetes. For example, studies have shown that SLC35E4 is involved in the regulation of ion transport in the heart, which may contribute to the development of these conditions. Similarly, SLC35E4 has been shown to be involved in the regulation of metabolism, which may contribute to the development of obesity and other metabolic disorders.

In addition to its involvement in disease, SLC35E4 is also a potential biomarker for a number of diseases. Its unique expression pattern and involvement in cellular processes make it an attractive target for diagnostic tests and potential therapeutic interventions. For example, SLC35E4 has been shown to be involved in the regulation of cellular processes that are important in the development and progression of certain cancers, including pancreatic cancer. This suggests that SLC35E4 may be a useful biomarker for the detection and treatment of these cancers.

Overall, SLC35E4 is a protein that is involved in a number of important cellular processes throughout the body. Its unique expression pattern and involvement in the regulation of various diseases make it an attractive target for drug development and potential therapeutic interventions. While further research is needed to fully understand the role of SLC35E4 in disease, its potential as a drug target and biomarker make it a promising area of study.

Protein Name: Solute Carrier Family 35 Member E4

Functions: Putative transporter

The "SLC35E4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35E4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets